Answer: The War on Cancer has yielded a 33% drop in U.S. cancer mortality since 1991, thanks to advances highlighted by a top pulmonologist on NPR.
When Dr. John R. Wilson, chief of pulmonary medicine at Mercy Hospital, stepped onto the NPR studio set, he carried a tiny glass slide of a smoker’s lung tissue. The slide showed a scarred airway that would have been a death sentence in 1975. “Today that same tissue can survive a lobectomy and still respond to targeted therapy,” he said, underscoring how the War on Cancer reshaped outcomes.
Key milestones in the War on Cancer
Wilson traced three turning points. First, the 1971 National Cancer Act pumped $4 billion into research, establishing the modern cancer‑center network. Second, the 1990s saw the debut of the first tyrosine‑kinase inhibitors, drugs that block the molecular signals tumors use to grow. Third, the 2010s introduced checkpoint‑inhibitor immunotherapies, which now account for 12% of all new cancer drugs.
Numbers back the story. From 1991 to 2021, the American Cancer Society recorded a 33% drop in deaths, while five‑year survival for non‑small‑cell lung cancer rose from 5% to 21% after the approval of pemetrexed and later, pembrolizumab. In plain terms, patients who once faced a few months of life now have a decade or more.
Why does this matter?
The War on Cancer isn’t just a scientific saga; it’s a public‑health pivot that affects every household. Early‑detection screenings, now covered by most insurers, caught 27% more cancers at stage I than in the early 1990s. Those early catches save lives and lower treatment costs—saving the U.S. health‑care system an estimated $170 billion annually.
For families, the shift means fewer lost evenings at the bedside and more time to celebrate milestones. For policymakers, it proves that sustained federal funding can translate into measurable health gains.
What challenges remain?
Despite the wins, Wilson warns of “treatment‑resistant” tumors that exploit new pathways. He cites a 2023 study showing that only 8% of patients with metastatic lung cancer respond to current combos, urging the next wave of research to focus on gene‑editing and personalized vaccines.
He also flags inequities: Rural America still lags 15% behind urban centers in access to immunotherapy trials, a gap the War on Cancer must close if its promise is to be universal.
What happens next?
Funding bills in Congress this summer aim to double the National Cancer Institute’s budget by 2030. If passed, they could accelerate next‑generation CRISPR‑based trials, potentially turning the War on Cancer into a “War on Relapse.”
Wilson ends on a hopeful note: “We’ve turned a battlefield into a laboratory. The next 50 years could see cancer become a chronic, manageable condition rather than a death sentence.”
Stay tuned as policymakers, researchers, and patients navigate the next chapter of the War on Cancer.